Tarsus Total Stockholder Equity vs Long Term Debt Analysis

TARS Stock

USD 32.96 1.78 5.12%

Tarsus PharmaceuticalsI financial indicator trend analysis is much more than just breaking down Tarsus PharmaceuticalsInc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tarsus PharmaceuticalsInc is a good investment. Please check the relationship between Tarsus PharmaceuticalsI Total Stockholder Equity and its Long Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Total Stockholder Equity vs Long Term Debt

Total Stockholder Equity vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tarsus PharmaceuticalsInc Total Stockholder Equity account and Long Term Debt. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Tarsus PharmaceuticalsI's Total Stockholder Equity and Long Term Debt is 0.53. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Tarsus PharmaceuticalsInc, assuming nothing else is changed. The correlation between historical values of Tarsus PharmaceuticalsI's Total Stockholder Equity and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Tarsus PharmaceuticalsInc are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Stockholder Equity i.e., Tarsus PharmaceuticalsI's Total Stockholder Equity and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.53

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Long Term Debt

Long-term debt is a debt that Tarsus PharmaceuticalsInc has held for over one year. Long-term debt appears on Tarsus PharmaceuticalsInc balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Tarsus PharmaceuticalsInc balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Tarsus PharmaceuticalsI's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tarsus PharmaceuticalsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At this time, Tarsus PharmaceuticalsI's Tax Provision is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 84.3 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.87 in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	312K	325K	628K	659.4K
Total Operating Expenses	67.1M	87.6M	159.0M	167.0M

Reconciled Depreciation Total Operating Expenses

Tarsus PharmaceuticalsI fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment
Total Assets		0.72	0.81	0.98	0.98	0.89	-0.87	-0.81	0.85	0.92	0.76	1.0	0.65	1.0	0.96	0.35	0.74	0.92	0.65	0.99	0.76	1.0	1.0	1.0	1.0	0.96
Other Current Liab	0.72		0.98	0.65	0.65	0.93	-0.75	-0.98	0.94	0.69	0.98	0.69	0.99	0.7	0.7	0.39	0.92	0.91	0.65	0.68	0.97	0.71	0.72	0.69	0.72	0.63
Total Current Liabilities	0.81	0.98		0.76	0.75	0.98	-0.81	-0.99	0.99	0.76	0.99	0.79	0.96	0.79	0.78	0.37	0.93	0.96	0.66	0.78	0.99	0.8	0.81	0.78	0.81	0.7
Total Stockholder Equity	0.98	0.65	0.76		1.0	0.85	-0.86	-0.75	0.8	0.9	0.71	0.98	0.58	0.98	0.9	0.16	0.71	0.9	0.49	1.0	0.71	0.98	0.98	0.98	0.98	0.96
Net Tangible Assets	0.98	0.65	0.75	1.0		0.84	-0.85	-0.75	0.8	0.91	0.7	0.98	0.58	0.98	0.9	0.17	0.7	0.89	0.51	1.0	0.7	0.98	0.98	0.98	0.98	0.96
Property Plant And Equipment Net	0.89	0.93	0.98	0.85	0.84		-0.91	-0.96	0.98	0.87	0.97	0.87	0.89	0.87	0.86	0.34	0.95	0.98	0.64	0.87	0.97	0.88	0.89	0.87	0.89	0.81
Net Debt	-0.87	-0.75	-0.81	-0.86	-0.85	-0.91		0.77	-0.81	-0.97	-0.81	-0.87	-0.69	-0.86	-0.87	-0.3	-0.9	-0.87	-0.56	-0.85	-0.83	-0.87	-0.87	-0.87	-0.87	-0.89
Retained Earnings	-0.81	-0.98	-0.99	-0.75	-0.75	-0.96	0.77		-0.98	-0.74	-0.98	-0.78	-0.97	-0.79	-0.78	-0.39	-0.91	-0.95	-0.69	-0.78	-0.97	-0.8	-0.81	-0.78	-0.81	-0.7
Accounts Payable	0.85	0.94	0.99	0.8	0.8	0.98	-0.81	-0.98		0.78	0.97	0.83	0.92	0.83	0.81	0.35	0.91	0.97	0.65	0.82	0.97	0.84	0.85	0.83	0.85	0.73
Cash	0.92	0.69	0.76	0.9	0.91	0.87	-0.97	-0.74	0.78		0.76	0.91	0.63	0.91	0.9	0.31	0.84	0.85	0.6	0.89	0.78	0.92	0.92	0.91	0.92	0.92
Non Current Assets Total	0.76	0.98	0.99	0.71	0.7	0.97	-0.81	-0.98	0.97	0.76		0.73	0.98	0.74	0.74	0.36	0.96	0.93	0.65	0.73	1.0	0.76	0.76	0.73	0.76	0.66
Cash And Short Term Investments	1.0	0.69	0.79	0.98	0.98	0.87	-0.87	-0.78	0.83	0.91	0.73		0.62	0.99	0.96	0.34	0.72	0.91	0.63	0.99	0.74	1.0	1.0	1.0	1.0	0.97
Net Receivables	0.65	0.99	0.96	0.58	0.58	0.89	-0.69	-0.97	0.92	0.63	0.98	0.62		0.63	0.64	0.39	0.9	0.87	0.65	0.61	0.96	0.65	0.66	0.62	0.66	0.54
Common Stock Total Equity	1.0	0.7	0.79	0.98	0.98	0.87	-0.86	-0.79	0.83	0.91	0.74	0.99	0.63		0.96	0.35	0.71	0.9	0.66	0.98	0.74	1.0	1.0	0.99	1.0	0.96
Common Stock Shares Outstanding	0.96	0.7	0.78	0.9	0.9	0.86	-0.87	-0.78	0.81	0.9	0.74	0.96	0.64	0.96		0.57	0.72	0.87	0.8	0.9	0.75	0.96	0.96	0.96	0.96	0.93
Non Current Liabilities Total	0.35	0.39	0.37	0.16	0.17	0.34	-0.3	-0.39	0.35	0.31	0.36	0.34	0.39	0.35	0.57		0.26	0.3	0.91	0.19	0.37	0.35	0.36	0.34	0.36	0.28
Other Current Assets	0.74	0.92	0.93	0.71	0.7	0.95	-0.9	-0.91	0.91	0.84	0.96	0.72	0.9	0.71	0.72	0.26		0.89	0.55	0.71	0.97	0.73	0.74	0.71	0.74	0.68
Other Stockholder Equity	0.92	0.91	0.96	0.9	0.89	0.98	-0.87	-0.95	0.97	0.85	0.93	0.91	0.87	0.9	0.87	0.3	0.89		0.61	0.91	0.93	0.92	0.92	0.91	0.92	0.85
Total Liab	0.65	0.65	0.66	0.49	0.51	0.64	-0.56	-0.69	0.65	0.6	0.65	0.63	0.65	0.66	0.8	0.91	0.55	0.61		0.52	0.65	0.65	0.66	0.63	0.66	0.55
Net Invested Capital	0.99	0.68	0.78	1.0	1.0	0.87	-0.85	-0.78	0.82	0.89	0.73	0.99	0.61	0.98	0.9	0.19	0.71	0.91	0.52		0.73	0.99	0.98	0.98	0.98	0.96
Property Plant And Equipment Gross	0.76	0.97	0.99	0.71	0.7	0.97	-0.83	-0.97	0.97	0.78	1.0	0.74	0.96	0.74	0.75	0.37	0.97	0.93	0.65	0.73		0.76	0.76	0.73	0.76	0.66
Total Current Assets	1.0	0.71	0.8	0.98	0.98	0.88	-0.87	-0.8	0.84	0.92	0.76	1.0	0.65	1.0	0.96	0.35	0.73	0.92	0.65	0.99	0.76		1.0	1.0	1.0	0.96
Capital Stock	1.0	0.72	0.81	0.98	0.98	0.89	-0.87	-0.81	0.85	0.92	0.76	1.0	0.66	1.0	0.96	0.36	0.74	0.92	0.66	0.98	0.76	1.0		1.0	1.0	0.96
Net Working Capital	1.0	0.69	0.78	0.98	0.98	0.87	-0.87	-0.78	0.83	0.91	0.73	1.0	0.62	0.99	0.96	0.34	0.71	0.91	0.63	0.98	0.73	1.0	1.0		1.0	0.97
Common Stock	1.0	0.72	0.81	0.98	0.98	0.89	-0.87	-0.81	0.85	0.92	0.76	1.0	0.66	1.0	0.96	0.36	0.74	0.92	0.66	0.98	0.76	1.0	1.0	1.0		0.96
Property Plant Equipment	0.96	0.63	0.7	0.96	0.96	0.81	-0.89	-0.7	0.73	0.92	0.66	0.97	0.54	0.96	0.93	0.28	0.68	0.85	0.55	0.96	0.66	0.96	0.96	0.97	0.96

Click cells to compare fundamentals

Tarsus PharmaceuticalsI Account Relationship Matchups

Tarsus PharmaceuticalsI fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	58.3M	172.0M	178.9M	227.9M	266.2M	166.0M
Other Current Liab	299K	2.9M	795K	4.8M	18.4M	19.3M
Total Current Liabilities	819K	5.4M	11.5M	15.4M	36.9M	38.8M
Total Stockholder Equity	(6.0M)	166.0M	166.7M	192.9M	197.0M	131.1M
Net Tangible Assets	(6.0M)	166.0M	166.7M	192.9M	221.8M	114.0M
Property Plant And Equipment Net	280K	1.2M	1.8M	1.5M	3.3M	3.5M
Net Debt	(57.8M)	(167.3M)	(169.4M)	(51.5M)	(193.2M)	(183.6M)
Retained Earnings	(6.0M)	(32.8M)	(46.7M)	(108.8M)	(244.7M)	(232.4M)
Accounts Payable	456K	2.2M	8.7M	9.9M	18.1M	19.1M
Cash	58.0M	168.1M	171.3M	71.7M	224.9M	127.7M
Non Current Assets Total	286K	1.3M	3.0M	2.5M	10.1M	10.6M
Cash And Short Term Investments	58.0M	168.1M	171.8M	217.0M	227.4M	154.9M
Net Receivables	36K	20K	92K	3.6M	17.7M	18.6M
Common Stock Shares Outstanding	19.5M	20.3M	20.6M	24.6M	29.4M	21.8M
Liabilities And Stockholders Equity	58.3M	172.0M	178.9M	227.9M	266.2M	166.0M
Non Current Liabilities Total	63.5M	605K	699K	19.5M	32.3M	22.0M
Capital Lease Obligations	164K	831K	1.9M	773K	398K	743.8K
Other Current Assets	22K	2.5M	4.0M	4.8K	7.9M	8.3M
Other Stockholder Equity	27K	198.8M	213.4M	301.7M	441.6M	463.7M
Total Liab	64.3M	6.0M	12.2M	35.0M	69.2M	34.9M
Net Invested Capital	(6.0M)	166.0M	166.7M	212.3M	226.8M	140.2M
Property Plant And Equipment Gross	280K	548K	1.8M	957K	4.6M	4.9M
Total Current Assets	58.0M	170.7M	176.0M	225.4M	256.1M	162.9M
Net Working Capital	57.2M	165.3M	164.5M	209.9M	219.2M	150.0M
Property Plant Equipment	280K	1.2M	755K	957K	1.1M	711.5K

Pair Trading with Tarsus PharmaceuticalsI

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tarsus PharmaceuticalsI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tarsus PharmaceuticalsI will appreciate offsetting losses from the drop in the long position's value.

Moving against Tarsus Stock

0.41

PPERY

Bank Mandiri Persero

Pair Corr

The ability to find closely correlated positions to Tarsus PharmaceuticalsI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tarsus PharmaceuticalsI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tarsus PharmaceuticalsI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tarsus PharmaceuticalsInc to buy it.

The correlation of Tarsus PharmaceuticalsI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tarsus PharmaceuticalsI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tarsus PharmaceuticalsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Tarsus PharmaceuticalsI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Tarsus PharmaceuticalsInc is a strong investment it is important to analyze Tarsus PharmaceuticalsI's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tarsus PharmaceuticalsI's future performance. For an informed investment choice regarding Tarsus Stock, refer to the following important reports:

How To Invest In Tarsus

Details

Is Tarsus Stock a good investment?

Details

What is Tarsus PharmaceuticalsI's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Tarsus Stock analysis

When running Tarsus PharmaceuticalsI's price analysis, check to measure Tarsus PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus PharmaceuticalsI is operating at the current time. Most of Tarsus PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Tarsus PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Tarsus PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.

	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Transaction History View history of all your transactions and understand their impact on performance
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum

Is Tarsus PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tarsus PharmaceuticalsI. If investors know Tarsus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tarsus PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.75)

Revenue Per Share

1.35

Quarterly Revenue Growth

10.046

Return On Assets

(0.35)

Return On Equity

(0.66)

The market value of Tarsus PharmaceuticalsInc is measured differently than its book value, which is the value of Tarsus that is recorded on the company's balance sheet. Investors also form their own opinion of Tarsus PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Tarsus PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tarsus PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Tarsus PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tarsus PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tarsus PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tarsus PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tarsus Total Stockholder Equity vs Long Term Debt Analysis

Total Stockholder Equity vs Long Term Debt

Total Stockholder Equity vs Long Term Debt Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Long Term Debt

Tarsus PharmaceuticalsI fundamental ratios Correlations

Tarsus PharmaceuticalsI Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tarsus PharmaceuticalsI fundamental ratios Accounts

Pair Trading with Tarsus PharmaceuticalsI

Moving against Tarsus Stock

Complementary Tools for Tarsus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Common Stock Total Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Capital Stock	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Common Stock	+ 1.0	Total Assets

Retained Earnings	- 0.99	Total Current Liabilities
Non Current Assets Total	- 0.98	Retained Earnings
Accounts Payable	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Other Current Liab
Property Plant And Equipment Gross	- 0.97	Retained Earnings
Net Receivables	- 0.97	Retained Earnings